Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
007460.KS
Top 10 Correlated ETFs
007460.KS
Top 10 Correlated Stocks
007460.KS
Financial details
Company Rating
Neutral
Market Cap
875.12B
Income
-11.42B
Revenue
151.62B
Book val./share
1827.92
Cash/share
510.19
Dividend
-
Dividend %
-
Employees
67
Optionable
No
Shortable
Yes
Earnings
-
P/E
-19.01
Forward P/E
-
PEG
3.19
P/S
1.43
P/B
0.56
P/C
2.02
P/FCF
14.59
Quick Ratio
2.93
Current Ratio
13.61
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-110.69
EPS next Y
-
EPS next Q
-
EPS this Y
-61.27%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
25.76%
Revenue Q/Q
-11.11%
EPS Q/Q
132.79%
-
-
-
-
SMA20
-20.37%
SMA50
-28.47%
SMA100
-31.21%
Inst Own
-
Inst Trans
-
ROA
-1%
ROE
-3%
ROC
-
Gross Margin
22%
Oper. Margin
-2%
Profit Margin
-8%
Payout
-
Shs Outstand
760.97M
Shs Float
97.23M
-
-
-
-
Target Price
-
52W Range
1135.0-2110.0
52W High
-51.18%
52W Low
-9.25%
RSI
22.02
Rel Volume
1.01
Avg Volume
3.64M
Volume
3.67M
Perf Week
-21.37%
Perf Month
-31.1%
Perf Quarter
-32.46%
Perf Half Y
-32.24%
-
-
-
-
Beta
1.06795
-
-
Volatility
49.31%, 143.32%
Prev Close
-5.5%
Price
1030
Change
-3.29%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 2.25K | 1K | 572.32 | 749.56 | 832.72 | |
| Net income per share | 117.21 | -631.71 | -79.28 | -274.08 | -106.13 | |
| Operating cash flow per share | 404.31 | -29.3 | -8.16 | 132.85 | -50.73 | |
| Free cash flow per share | 400.39 | -108.77 | -67.97 | 114.45 | -63.2 | |
| Cash per share | 9.91K | 2.36K | 1.28K | 1.4K | 942.14 | |
| Book value per share | 7.49K | 3.85K | 1.97K | 1.88K | 1.98K | |
| Tangible book value per share | 7.44K | 3.84K | 3.76K | 4.05K | 4.13K | |
| Share holders equity per share | 7.49K | 3.85K | 1.97K | 1.88K | 1.98K | |
| Interest debt per share | 5.02K | 3.74K | 688.25 | 535.81 | 532.94 | |
| Market cap | 287.58B | 148.92B | 386.24B | 308.71B | 242.56B | |
| Enterprise value | 274.11B | 258.48B | 399.52B | 297.75B | 259.16B | |
| P/E ratio | 122.85 | -4.64 | -35.63 | -6.64 | -13.47 | |
| Price to sales ratio | 6.41 | 2.92 | 4.94 | 2.43 | 1.72 | |
| POCF ratio | 35.62 | -100 | -346.2 | 13.7 | -28.19 | |
| PFCF ratio | 35.97 | -26.94 | -41.56 | 15.9 | -22.63 | |
| P/B Ratio | 1.92 | 0.76 | 1.43 | 0.97 | 0.72 | |
| PTB ratio | 1.92 | 0.76 | 1.43 | 0.97 | 0.72 | |
| EV to sales | 6.11 | 5.06 | 5.11 | 2.34 | 1.83 | |
| Enterprise value over EBITDA | 55.77 | -40.07 | 2.57K | -6.86 | 260.49 | |
| EV to operating cash flow | 33.95 | -173.56 | -358.11 | 13.21 | -30.11 | |
| EV to free cash flow | 34.28 | -46.75 | -42.99 | 15.34 | -24.18 | |
| Earnings yield | 0.01 | -0.22 | -0.03 | -0.15 | -0.07 | |
| Free cash flow yield | 0.03 | -0.04 | -0.02 | 0.06 | -0.04 | |
| Debt to equity | 0.34 | 0.47 | 0.03 | 0.08 | 0 | |
| Debt to assets | 0.44 | 0.51 | 0.2 | 0.17 | 0.15 | |
| Net debt to EBITDA | -2.74 | -16.98 | 85.35 | 0.25 | 16.69 | |
| Current ratio | 3.91 | 1.42 | 3.19 | 5.11 | 4.37 | |
| Interest coverage | 1.2 | 0.08 | 0.28 | 0.76 | -0.23 | |
| Income quality | 3.45 | 0.05 | 0.1 | -0.48 | 0.48 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0.03 | 0.03 | 0.03 | |
| Research and developement to revenue | 0.01 | 0.09 | 0.02 | 0.01 | 0.01 | |
| Intangibles to total assets | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to operating cash flow | -0.01 | 2.71 | 7.33 | -0.14 | 0.25 | |
| Capex to revenue | 0 | -0.08 | -0.1 | -0.02 | -0.01 | |
| Capex to depreciation | -0.04 | -1.99 | -2.52 | -0.72 | -0.5 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.44K | 7.39K | 1.88K | 3.41K | 2.17K | |
| ROIC | 0.01 | 0.01 | 0 | 0.01 | 0 | |
| Return on tangible assets | 0.01 | -0.08 | -0.02 | -0.06 | -0.02 | |
| Graham Net | 4.14K | -1.52K | 394.42 | 600.42 | 297.77 | |
| Working capital | 159.94B | 41.51B | 238.45B | 349.41B | 373.57B | |
| Tangible asset value | 148.57B | 195.42B | 513.89B | 686.3B | 701.3B | |
| Net current asset value | 97.45B | -58.31B | 217.47B | 290.24B | 364.58B | |
| Invested capital | 0.66 | 0.87 | 0.32 | 0.27 | 0.24 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.27B | 0 | 1.55B | 1.45B | 1.65B | |
| Average inventory | 10.85B | 11.24B | 17.35B | 17.3B | 19.1B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 27.8 | 0 | 10.22 | 5.72 | 6.16 | |
| Days of inventory on hand | 39.54 | 45.2 | 107.86 | 68.14 | 69.35 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 13.13 | 0 | 35.72 | 63.76 | 59.27 | |
| Inventory turnover | 9.23 | 8.07 | 3.38 | 5.36 | 5.26 | |
| ROE | 0.02 | -0.16 | -0.04 | -0.15 | -0.05 | |
| Capex per share | -3.92 | -79.47 | -59.81 | -18.4 | -12.46 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 193.17 | 176.65 | 468.02 | 520.81 | 176.84 | |
| Net income per share | -60.91 | 39 | -72.5 | -23.2 | -54 | |
| Operating cash flow per share | -1.89 | 23.12 | -117.64 | -8.42 | 109.22 | |
| Free cash flow per share | -2.99 | 18.16 | -124.27 | -15.91 | 107.21 | |
| Cash per share | 1.01K | 969.23 | 1.98K | 0 | 510.19 | |
| Book value per share | 1.68K | 1.73K | 4.17K | 4.24K | 1.83K | |
| Tangible book value per share | 3.59K | 3.59K | 8.71K | 8.83K | 3.57K | |
| Share holders equity per share | 1.68K | 1.73K | 4.17K | 4.24K | 1.83K | |
| Interest debt per share | 453.18 | 399.52 | 1.02K | 126.11 | 111.65 | |
| Market cap | 429.58B | 372.59B | 135.66B | 122.78B | 360.4B | |
| Enterprise value | 413.63B | 365.33B | 152.26B | 122.78B | 276.55B | |
| P/E ratio | -9.23 | 12.15 | -5.81 | -16.44 | -7.92 | |
| Price to sales ratio | 11.65 | 10.73 | 3.6 | 2.93 | 9.67 | |
| POCF ratio | -1.19K | 81.96 | -14.32 | -181.14 | 15.66 | |
| PFCF ratio | -751.49 | 104.32 | -13.56 | -95.85 | 15.95 | |
| P/B Ratio | 1.34 | 1.09 | 0.4 | 0.36 | 0.94 | |
| PTB ratio | 1.34 | 1.09 | 0.4 | 0.36 | 0.94 | |
| EV to sales | 11.22 | 10.52 | 4.04 | 2.93 | 7.42 | |
| Enterprise value over EBITDA | -43.37 | 22.11 | -115.3 | 10.71 | -31.42 | |
| EV to operating cash flow | -1.15K | 80.36 | -16.08 | -181.14 | 12.01 | |
| EV to free cash flow | -723.59 | 102.29 | -15.22 | -95.85 | 12.24 | |
| Earnings yield | -0.03 | 0.02 | -0.04 | -0.02 | -0.03 | |
| Free cash flow yield | 0 | 0.01 | -0.07 | -0.01 | 0.06 | |
| Debt to equity | 0.04 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.18 | 0.14 | 0.15 | 0.14 | 0.06 | |
| Net debt to EBITDA | 1.67 | -0.44 | -12.57 | 0 | 9.53 | |
| Current ratio | 3.79 | 4.35 | 4.37 | 5.04 | 13.61 | |
| Interest coverage | -0.49 | -0.35 | 0.03 | 0 | -0.67 | |
| Income quality | 0.03 | 0.59 | 1.62 | 0.36 | -2.02 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.23 | 0.02 | |
| Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0 | 0.03 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.59 | -0.21 | 0.06 | 0.89 | -0.02 | |
| Capex to revenue | -0.01 | -0.03 | -0.01 | -0.01 | -0.01 | |
| Capex to depreciation | -0.21 | -0.89 | -0.47 | -0.66 | -0.46 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.52K | 1.23K | 2.61K | 1.49K | 1.49K | |
| ROIC | 0 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | -0.01 | 0.01 | -0.01 | 0 | -0.01 | |
| Graham Net | 271.69 | 422.15 | 627.34 | -1.39K | 350.34 | |
| Working capital | 335.67B | 369.12B | 373.57B | 410.16B | 463.11B | |
| Tangible asset value | 684.72B | 705.22B | 701.3B | 0 | 751.86B | |
| Net current asset value | 305.32B | 361.16B | 364.58B | 399.43B | 453.67B | |
| Invested capital | 0.26 | 0.22 | 0.24 | 0 | 0.05 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 5.91 | 5.74 | 5.84 | 0 | 7.75 | |
| Days of inventory on hand | 63.15 | 69.78 | 65.77 | 0 | 75.1 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 15.23 | 15.69 | 15.41 | 0 | 11.61 | |
| Inventory turnover | 1.43 | 1.29 | 1.37 | 0 | 1.2 | |
| ROE | -0.04 | 0.02 | -0.02 | -0.01 | -0.03 | |
| Capex per share | -1.11 | -4.96 | -6.63 | -7.49 | -2.02 |
Frequently Asked Questions
What is Aprogen Medicines Inc. stock symbol ?
Aprogen Medicines Inc. is a US stock and trading under the symbol 007460.KS
What is Aprogen Medicines Inc. stock quote today ?
Aprogen Medicines Inc. stock price is $1030 today.
Is Aprogen Medicines Inc. stock public?
Yes, Aprogen Medicines Inc. is a publicly traded company.
Company Profile
- Volume Average 3.64M
- Market Capitalization 875.12B
- Employee 67
- Headquarters Seongnam-si,US
- IPO Date 2005-09-29
-
Website
https://www.aprogen-kic.com 
Aprogen Medicines Inc. designs, manufactures, and maintains plant facilities for steelwork, petrochemistry, shipbuilding, power plant, and LNG base industries in South Korea. The company also offers thermal and cold spray services; and clad rolls, clad plates, wear plates, clad pipes and fittings, and plasma transferred arcs. In addition, it provides Nukon system, a special heat-preservation system that keeps the pipe facility of the internal equipment of the containment building working safely in the pressurized water reactor power plant; foamglas, a cellular glass insulation product; and fireproof insulation works in the POSCO furnaces and boilers. The company was formerly known as Aprogen KIC Inc. and changed its name to Aprogen Medicines Inc. April 2021. Aprogen Medicines Inc. was founded in 1971 and is based in Seongnam-si, South Korea.
